Jain P, Badgujar L, Spoorendonk JA, Buesch K. “Clinical Efficacy and Safety of Therapeutic Interventions used in Friedreich Ataxia: A Systematic Literature Review” [Therapeutic Advances in Rare Disease – SAGE Journal 2022]
Buesch K and Zhang R. “A Systematic Review of Disease Prevalence, Health-Related Quality of Life, and Economic Outcomes Associated with Friedreich´s Ataxia” [Curr Med Res Opin. 2022]
Acaster S, Williams K, Skrobanski H, Buesch K. “Using the EQ-5D to measure caregiver health-related quality of life in rare pediatric disease: a study in aromatic L-amino acid decarboxylase deficiency” [Future Neurology 2022]
Williams K, Buesch K*, Acaster S* (*shared). “Symptoms and impacts of nonsense mutation Duchenne muscular dystrophy at different stages of ambulation” [Future Neurology 2022]
Landfeldt E, Zhang R, Childs AM, Johannsen J, O'Rourke D, Sejersen T, Strautmanis J, Schara-Schmidt U, Tulinius M, Walter MC, Willis T, Buesch K. “Assessment of face validity of a disease model of nonsense mutation Duchenne muscular dystrophy: a multi-national Delphi panel study” [J Med Econ. 2022]
Buesch K, Zhang R, Szczepańska K, Veličković V, Turner L, Despotović M, Đorđević B, Russell A. “Burden and severity of disease of aromatic L-amino acid decarboxylase deficiency: a systematic literature review” [Curr Med Res Opin. 2022]
Saberian S, Rowan P, Hammes F, Patel P, Fernandez-Cortes F, Beitia Ortiz de Zarate I, Buesch K. “Burden of illness of aromatic L-amino acid decarboxylase deficiency: a survey of physicians in southern Europe” [Curr Med Res Opin. 2022]
Ferizovic N, Summers J, de Zárate IBO, Werner C, Jiang J, Landfeldt E, Buesch K. “Prognostic indicators of disease progression in Duchenne muscular dystrophy: A literature review and evidence synthesis” [PLoS One 2022]
Williams K, Skrobanski H, Buesch K*, Acaster S* (*shared). “Symptoms and impacts of aromatic l-amino acid decarboxylase (AADC) deficiency among individuals with different levels of motor function” [Orphanet Journal of Rare Diseases 2022]
Andreozzi V, Labisa P, Mota M, Monteiro S, Alves R, Almeida J, Vandewalle B, Felix J, Buesch K, Canhão H, Beitia Ortiz de Zarate I. “Quality of life and informal care burden associated with Duchenne Muscular Dystrophy in Portugal: the COIDUCH study” [Health and Quality of Life Outcomes 2022]
Labisa P, Andreozzi V, Mota M, Monteiro S, Alves R, Almeida J, Vandewalle B, Felix J, Buesch K, Canhão H, Beitia Ortiz de Zarate I. “Cost of Illness in Patients with Duchenne Muscular Dystrophy in Portugal: The COIDUCH Study" [Pharmacoecon Open 2022]
Smith AB, Hanbury A, Whitty J, Beitia Ortiz de Zarate I, Hammes F, de Pouvourville G, Buesch K. “A Discrete Choice Experiment to Derive Health Utilities for Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency in France” [Patient Relat Outcome Meas. 2022]
Landfeldt E*, Ferizović N*, Buesch K (*shared). “Timing of Clinical Interventions in Patients With Duchenne Muscular Dystrophy: A Systematic Review and Grading of Evidence” [Journal of Neuromuscular Diseases 2022]
Smith AB, Hanbury A, Buesch K. “Eliciting health state utilities for Aromatic L-amino Acid Decarboxylase (AADC) deficiency: a UK vignette study” [Journal of Patient Reported Outcomes 2021]
Williams K, Davidson I, Rance M, Boehnke A, Buesch K*, Acaster S* (*shared). “Symptoms and impacts of ambulatory nonsense mutation Duchenne muscular dystrophy: a qualitative study and the development of a patient-centred conceptual model” [J Patient Rep Outcomes 2021]
Williams K, Davidson I, Rance M, Buesch K*, Acaster S* (*shared). “A qualitative study on the impact of caring for an ambulatory individual with nonsense mutation Duchenne muscular dystrophy” [J Patient Rep Outcomes 2021]
Smith AB, Hanbury A, Beitia Ortiz de Zarate I, Hammes F, de Pouvourville G, Buesch K. “Eliciting Health State Utilities for Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency: A Vignette Study in France” [Patient Relat Outcome Meas. 2021]
Skrobanski H, Williams K, Werner C, O'Neill S, Buesch K*, Acaster S* (*shared). “The impact of caring for an individual with aromatic l-amino acid decarboxylase (AADC) deficiency: a qualitative study and the development of a conceptual model” [Curr Med Res Opin. 2021]
Williams K, Skrobanski H, Werner C, O'Neill S, Buesch K*, Acaster S* (*shared). “Symptoms and impact of aromatic l-amino acid decarboxylase (AADC) deficiency: a qualitative study and the development of a patient-centred conceptual model” [Curr Med Res Opin. 2021]
Smith AB, Hanbury A, Whitty JA, Buesch K. “A Discrete Choice Experiment to Derive Health Utilities for Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency” [Patient Relat Outcome Meas. 2021]
Hanbury A, Smith AB, Buesch K. “Deriving Vignettes for the Rare Disease AADC Deficiency Using Parent, Caregiver and Clinician Interviews to Evaluate the Impact on Health-Related Quality of Life” [Patient Relat Outcome Meas. 2021]
Büsch K, Hansson F, Holton M, Lagging M, Westin J, Kövamees J, Sällberg M, Söderholm J. “Sick leave and disability pension in patients with chronic hepatitis C compared with a matched general population: a nationwide register study” [BMJ Open 2020]
Kåberg M, Larsson SB, Jerkeman A, Nystedt A, Duberg AS, Kövamees J, Ydreborg M, Aleman S, Büsch K, Alanko Blomé M, Weiland O, Söderholm J. “High risk of non-alcoholic liver disease mortality in patients with chronic hepatitis C with illicit substance use disorder” [Scand J Gastroenterol. 2020]
Aleman S, Söderholm J, Büsch K, Kövamees J, Duberg AS. “Frequent loss to follow-up after diagnosis of hepatitis C virus infection: A barrier towards the elimination of hepatitis C virus” [Liver Int 2020]
Söderholm J, Yilmaz A, Svenningsson A, Büsch K, Wejstål R, Brolund A, Kövamees J, Sällberg M, Lagging M, Gisslén M. “Lower risk of multiple sclerosis in patients with chronic hepatitis C: a nationwide population-based registry study” [J Neurol. 2019]
Söderholm J, Millbourn C, Büsch K, Kövamees J, Schvarcz R, Lindahl K, Bruchfeld A. “Higher risk of renal disease in chronic hepatitis C patients: Antiviral therapy survival benefit in patients on hemodialysis” [J Hepatol. 2018]
Ludvigsson JF, Büsch K, Olén O, Askling J, Ekström-Smedby K, Ekbom A, Lindberg E, Neovius M. “Prevalence of paediatric inflammatory bowel disease in Sweden: a nationwide population-based register study” [BMC Gastroenterol. 2017]
Büsch K, Waldenström J, Lagging M, Aleman S, Weiland O, Kövamees J, Duberg AS, Söderholm S. “Prevalence and comorbidities of chronic Hepatitis C: a Nationwide Population-Based Register Study in Sweden” [Scandinavian Journal of Gastroenterology 2016]
Büsch K, Sonnenberg A, Bansback N. “Impact of inflammatory bowel disease on disability” [Current Gastroenterology Reports 2014]
Büsch K, da Silva SA, Holton M, Rabacow FM, Khalili H, Ludvigsson JF. “Sick leave and disability pension in inflammatory bowel disease: A systematic review” [Journal of Crohns & Colitis 2014]
Büsch K, Ludvigsson JF, Ekström-Smedby K, Ekbom A, Askling J, Neovius M. “Nationwide Prevalence of Inflammatory Bowel Disease in Sweden: A Population-Based Register Study” [Alimentary Pharmacology & Therapeutics 2014]
Bentley A, Filipovic I, Gooch K and Büsch K. “A cost-effectiveness analysis of respiratory syncytial virus (RSV) prophylaxis in infants in the United Kingdom” [Health Economics Review 2013]
Jacobs P, Lier D, Gooch K, Buesch K, Lorimer M, Mitchell I. “A Model of the Costs of Community and Nosocomial Paediatric Respiratory Syncytial Virus in Canadian Hospitals” [The Canadian journal of infectious diseases & medical microbiology 2013]
Augustin M, Chapnik J, Gupta S, Buesch K, Radtke M. “Psoriasis verursacht hohe Kosten, mindert die Produktivität am Arbeitsplatz und verringert die Lebensqualität” [Akt Dermatol. 2011]
Gooch K, Notario N, Schulz G, Gudkov K, Buesch K, Khong H, Campbell A. “A Comparison of Severe Respiratory Syncytial Virus (RSV) Risk Factors Between Preterm and Term Infants Hospitalized for Severe RSV in the Russian Federation” [Int Women's Health J. 2011]
Neovius K, Buesch K, Sandström K, Neovius M. “Cost-Effectiveness Analysis of Palivizumab as RSV-Prophylaxis in Preterm Infants in Sweden” [Acta Paed. 2011]
Hillemanns P, Petry KU, Largeron N, McAllister R, Tolley K, Büsch K. “Cost-effectiveness of a tetravalent human papillomavirus vaccine in Germany” [Journal of Public Health 2009]
Gillissen A, Juergens U, Büsch K. “Therapieadhärenz bei Asthma bronchiale. Methoden zur Verbesserung” [Dtsch Med Wochenschr. 2008]
Gillissen A, Büsch K, Juergens U. “Therapieadhärenz bei Asthma bronchiale. Definition – Einteilung –beeinflussende Faktoren” [Dtsch Med Wochenschr. 2007]
Neubauer S, Welte R, Beiche A, Buesch K, König H-H, Leidl R. “Mortality, morbidity and costs attributable to smoking in Germany: update and a 10 year comparison” [Tabacco control 2007]
